Agriculture · Founded 1990 · www.hindustanagrigenetics.co.in · BSE 519574 · · ISIN INE092301014
No Notes Added Yet
Business
Hindustan Agrigenetics Ltd. (HIND.AGRIGEN) operates in the Indian agriculture sector, specifically focusing on "Agrigenetics." This implies its core business involves the research, development, production, processing, and marketing of high-quality seeds, likely including hybrid and improved varieties, for various crops. The company's business model is centered on providing seeds designed to enhance crop yield, quality, and resistance to pests and diseases. It generates revenue by selling these seeds directly to farmers or through a network of distributors and dealers across different agricultural regions of India, aiming to improve farmer productivity and profitability.
Revenue Mix
Specific revenue mix details are not publicly available without financial reports. However, based on its focus on "Agrigenetics," the company's primary revenue drivers would likely come from:
Field Crops: Seeds for major staple crops such as maize, rice, wheat, cotton, and various pulses.
Vegetable Crops: Seeds for a range of commercially important vegetables.
While seeds would be the dominant segment, the company might also engage in the sale of other allied agricultural inputs or services, though this would be secondary to its core seed business.
Industry
The Indian agriculture sector is vast, fragmented, and heavily influenced by monsoon patterns, government policies, and global commodity prices. The seeds industry, a critical component, features a mix of large multinational corporations, well-established domestic players, and numerous regional companies. Competition is intense, driven by factors such as seed performance (yield, disease resistance), pricing, and distribution reach. Hindustan Agrigenetics Ltd. would be positioned among domestic seed companies, competing on the strength of its proprietary germplasm, localized research capabilities, brand recognition among farmers in its operational areas, and the effectiveness of its distribution network. The industry requires significant investment in R&D and strong farmer relationships.
MOAT
Without specific detailed information, potential competitive advantages (moats) for Hindustan Agrigenetics Ltd. could include:
Proprietary Germplasm & R&D: A strong pipeline of successful, high-performing, and regionally adapted seed varieties developed through in-house research.
Brand Reputation & Farmer Trust: Long-standing credibility and trust among farmers due to consistent product quality and reliable performance, fostering repeat purchases.
Extensive Distribution Network: A wide and efficient network of dealers and sales agents reaching diverse farming communities, particularly in key agricultural belts.
Localized Expertise: Deep understanding of specific agro-climatic conditions and farming practices in different regions of India, allowing for tailored product offerings.
Growth Drivers
Increasing Food Demand: India's growing population and rising disposable incomes drive sustained demand for agricultural produce, directly translating into demand for high-quality seeds.
Adoption of Hybrid Seeds: Continued shift among Indian farmers from traditional seeds to higher-yielding hybrid and improved varieties to enhance productivity.
Product Innovation: Introduction of new and superior seed varieties with enhanced yield potential, pest/disease resistance, and climate resilience.
Government Support: Favorable government policies promoting agricultural productivity, irrigation infrastructure, and schemes aimed at increasing farmer income.
Geographic and Crop Diversification: Expansion into new agricultural regions or diversifying the product portfolio to include seeds for a wider range of crops.
Risks
Monsoon Dependence: Indian agriculture's high reliance on monsoon rains makes the business vulnerable to erratic or deficient monsoons, impacting seed demand and crop output.
Regulatory & Policy Changes: Government interventions regarding seed pricing, quality standards, seed subsidies, or approval processes for new technologies (e.g., GM crops) can significantly impact profitability.
Intense Competition: Fierce competition from both large domestic and multinational seed companies, potentially leading to pricing pressures and market share erosion.
Pest & Disease Outbreaks: Unexpected outbreaks can damage crops, impact farmer sentiment, and reduce future seed demand.
R&D Failures: Significant investments in research and development do not guarantee the successful commercialization of new, market-winning seed varieties.
Counterfeit Products: The risk of imitation or counterfeit seeds entering the market, impacting legitimate sales and brand reputation.
Management & Ownership
In Indian companies like Hindustan Agrigenetics Ltd., it is common for promoter families or groups to hold a significant ownership stake and play a key role in management. The quality of management is crucial in the agriculture sector, requiring expertise in agricultural science, R&D, supply chain management, and a deep understanding of farmer needs and market dynamics. Specific details on the current management team's track record and exact ownership structure are not available without access to corporate filings or financial reports.
Outlook
Hindustan Agrigenetics Ltd. operates in a sector underpinned by fundamental long-term growth drivers, primarily the consistent demand for food from India's large and expanding population. The ongoing shift towards advanced farming practices and the adoption of superior seed varieties present significant opportunities for growth. However, the business is inherently cyclical and exposed to considerable external risks, including the unpredictable nature of monsoons, evolving government agricultural policies, and intense competitive dynamics. The company's sustained success will hinge on its ability to consistently innovate new, high-performing seed varieties, maintain strong relationships and trust with farmers, and efficiently manage its supply chain amidst these challenges.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Total Expenditure | 0 | 0 | -0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Operating Profit | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -0 | -0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -0 | -0 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -0 | -0 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -0 | -0 | 0 |
| Adjusted Earnings Per Share | 0.3 | 0.1 | 0.4 | 0.1 | -1.2 | 0.9 | 0.4 | -0.1 | -0.9 | 0.7 |
| #(Fig in Cr.) | Mar 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 1 | 1 | 0 |
| Total Income | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 1 | 1 | 0 |
| Total Expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| Operating Profit | -0 | 1 | 0 | 0 | -0 | -0 | -0 | -0 | 10 | 1 | -0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | 1 | 0 | 0 | -0 | -0 | -0 | -0 | 10 | 1 | -0 | 0 |
| Provision for Tax | 0 | 0 | 0 | 1 | -0 | -1 | -0 | -0 | 0 | 0 | -0 | 0 |
| Profit After Tax | -0 | 1 | 0 | -1 | -0 | 0 | -0 | -0 | 10 | 0 | -0 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | 1 | 0 | -1 | -0 | 0 | -0 | -0 | 10 | 0 | -0 | 0 |
| Adjusted Earnings Per Share | -0.2 | 1.5 | 0.2 | -1.3 | -0.3 | 0.7 | -0.3 | -0.2 | 22.4 | 1.1 | -0.7 | 0.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 0% | 0% | 0% |
| Operating Profit CAGR | -100% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -40% | -13% | NA% | NA% |
| ROE Average | -3% | 49% | 27% | 14% |
| ROCE Average | -2% | 50% | 27% | 14% |
| #(Fig in Cr.) | Mar 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 12 | 12 | 12 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -1 | -1 | -1 | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 |
| Total Current Liabilities | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 1 | 0 | 0 |
| Total Liabilities | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 7 | 11 | 12 | 12 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 7 | 11 | 12 | 11 |
| Total Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 7 | 11 | 12 | 12 |
| #(Fig in Cr.) | Mar 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 10 | 9 |
| Cash Flow from Operating Activities | -0 | -0 | -0 | -0 | -0 | -1 | 1 | 5 | -7 | 0 | 0 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | 0 | 0 | 1 | -1 | -0 | 12 | -1 | -4 |
| Cash Flow from Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 |
| Net Cash Inflow / Outflow | -0 | 0 | -0 | 0 | -0 | 0 | -0 | 5 | 5 | -1 | -4 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 10 | 9 | 5 |
| # | Mar 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.16 | 1.51 | 0.25 | -1.35 | -0.26 | 0.74 | -0.33 | -0.22 | 22.4 | 1.07 | -0.69 |
| CEPS(Rs) | -0.12 | 1.53 | 0.27 | -1.33 | -0.24 | 0.76 | -0.32 | -0.21 | 22.41 | 1.15 | -0.61 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 4.09 | 5.8 | 5.92 | 4.58 | 3.98 | 4.73 | 4.4 | 4.17 | 26.58 | 27.65 | 26.95 |
| Core EBITDA Margin(%) | -108.5 | -100.36 | -157.12 | -315.01 | -399.42 | -262.03 | -291.17 | -276.18 | -1054.61 | -421.25 | -1327.89 |
| EBIT Margin(%) | -51.42 | 1408.15 | 274.66 | 48.48 | -211.93 | -194.89 | -297.04 | -177.3 | 0 | 862.36 | -384.7 |
| Pre Tax Margin(%) | -51.66 | 1408.15 | 274.66 | 48.48 | -211.93 | -194.89 | -297.04 | -177.3 | 0 | 841.53 | -399.09 |
| PAT Margin (%) | -118.46 | 1061.2 | 173.5 | -1162.49 | -190.24 | 174.45 | -239.84 | -155.43 | 0 | 651.94 | -395.72 |
| Cash Profit Margin (%) | -91.16 | 1076.69 | 184.88 | -1149.4 | -172.95 | 177.85 | -233.38 | -151.47 | 0 | 703.19 | -349.16 |
| ROA(%) | -3.65 | 33.55 | 5.27 | -28.26 | -5.8 | 18.66 | -8.12 | -2.11 | 106.3 | 4.05 | -2.61 |
| ROE(%) | -3.76 | 30.46 | 4.26 | -25.68 | -6.18 | 17.05 | -7.25 | -5.15 | 145.7 | 3.93 | -2.54 |
| ROCE(%) | -1.63 | 40.42 | 6.75 | 1.07 | -6.89 | -19.05 | -8.98 | -5.87 | 146.43 | 5.2 | -2.47 |
| Receivable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payable days | 0 | 4609.7 | 18.04 | 51.91 | 214.81 | 159.89 | 179.32 | 125.74 | 101 | 99.81 | 45.63 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47.9 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.85 | 2.49 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 75.22 | 69.6 | 68.7 | 84.93 | 71.17 | 21.93 | 69.76 | -9.65 | -80.38 | 180.63 | 316.56 |
| EV/Core EBITDA(x) | -311.86 | 4.89 | 24.02 | 137.94 | -36.56 | -11.45 | -24.01 | 5.57 | -0.59 | 19.77 | -92.45 |
| Net Sales Growth(%) | 11.82 | 7.39 | 1.48 | -19.45 | 19.93 | 206.03 | -67.61 | 2.91 | 16.3 | -0.85 | 7.08 |
| EBIT Growth(%) | 74.91 | 3040.68 | -80.21 | -85.78 | -624.29 | -181.42 | 50.63 | 38.57 | 9048.84 | -93.73 | -147.77 |
| PAT Growth(%) | -92.63 | 1062.01 | -83.41 | -639.71 | 80.37 | 380.64 | -144.53 | 33.31 | 0 | -95.24 | -165 |
| EPS Growth(%) | -92.63 | 1062.01 | -83.41 | -639.71 | 80.37 | 380.64 | -144.53 | 33.3 | 0 | -95.24 | -165 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 1.6 | 7.43 | 11.42 | 11.18 | 7.01 | 4.38 | 1.92 | 1.11 | 22.4 | 158.21 | 330.73 |
| Quick Ratio(x) | 1.6 | 7.43 | 11.42 | 11.18 | 7.01 | 4.38 | 1.92 | 1.11 | 22.4 | 158.21 | 330.73 |
| Interest Cover(x) | -212.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41.39 | -26.72 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 29.42 | 28.4 | 9.61 | 9.47 | 8.2 | 8.17 | 25.35 | 25.35 | 25.35 | 25.35 |
| FII | 0.13 | 0.13 | 0.13 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| DII | 9.82 | 9.82 | 9.82 | 9.65 | 9.65 | 9.65 | 9.65 | 9.65 | 9.65 | 9.65 |
| Public | 60.64 | 61.65 | 80.44 | 80.58 | 81.85 | 81.88 | 64.71 | 64.71 | 64.71 | 64.71 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.13 | 0.12 | 0.04 | 0.04 | 0.04 | 0.04 | 0.11 | 0.11 | 0.11 | 0.11 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Public | 0.27 | 0.27 | 0.35 | 0.35 | 0.36 | 0.36 | 0.28 | 0.28 | 0.28 | 0.28 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | — | — | — | — |
| Operating Profit CAGR | -100% | — | — | — |
| PAT CAGR | — | — | — | — |
| Share Price CAGR | -40% | -13% | — | — |
| ROE Average | -3% | +49% | +27% | +14% |
| ROCE Average | -2% | +50% | +27% | +14% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 29.42 | 28.4 | 9.61 | 9.47 | 8.2 | 8.17 | 25.35 | 25.35 | 25.35 | 25.35 |
| FII | 0.13 | 0.13 | 0.13 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| DII | 9.82 | 9.82 | 9.82 | 9.65 | 9.65 | 9.65 | 9.65 | 9.65 | 9.65 | 9.65 |
| Public | 60.64 | 61.65 | 80.44 | 80.58 | 81.85 | 81.88 | 64.71 | 64.71 | 64.71 | 64.71 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.13 | 0.12 | 0.04 | 0.04 | 0.04 | 0.04 | 0.11 | 0.11 | 0.11 | 0.11 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Public | 0.27 | 0.27 | 0.35 | 0.35 | 0.36 | 0.36 | 0.28 | 0.28 | 0.28 | 0.28 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.